Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Wednesday, 23'rd Aug 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Wells Fargo Healthcare Co
Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data
08:45am, Wednesday, 23'rd Aug 2023
Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.80%,
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
01:32pm, Tuesday, 22'nd Aug 2023
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
Gilead Sciences told by FDA to pause patient enrollment in leukemia drug trials
10:41am, Monday, 21'st Aug 2023
Gilead Sciences, Inc. (NASDAQ:GILD) said the Food and Drug Administration (FDA) has put a clinical hold on its studies evaluating its investigation anti-CD47 immunotherapy magrolimab for acute myeloid
US FDA puts Gilead Sciences blood cancer drug studies on hold
08:52am, Monday, 21'st Aug 2023
Gilead Sciences said on Monday the U.S. Food and Drug Administration had placed a partial clinical hold on initiating new patients in the U.S. studies for drug to treat a type of blood cancer.
Gilead says FDA hits pause on study of leukemia treatment
08:47am, Monday, 21'st Aug 2023
Gilead Sciences Inc. GILD, -0.81% said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a treatment for acute myeloid leukemia. Screening an
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
02:44pm, Wednesday, 16'th Aug 2023
Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Gilead ties up with Tentarix for cancer, inflammatory disease therapies
08:49am, Tuesday, 15'th Aug 2023
Gilead Sciences said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.
The 3 Best Biotech Stocks to Buy in August
04:00pm, Wednesday, 09'th Aug 2023
Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus' spread. But medical innovations and technological breakthroughs are rapidly transforming the health
2 High-Yield Dividend Stocks to Buy on the Dip
05:26am, Tuesday, 08'th Aug 2023
Despite their falling stock prices, both of these companies have solid prospects. Pfizer has been busy making deals -- something that is already paying off.
Gilead Sciences: Mixed Signals, Again
05:47am, Monday, 07'th Aug 2023
Gilead Sciences has experienced a boom-bust-recovery cycle, with its fortunes changing after acquiring Pharmasset and obtaining a cure for HCV. Revenues have been stagnant for nearly a decade, with th
Is Gilead Sciences (GILD) Stock Worth Your Investment? A Comprehensive Valuation Analysis
06:34pm, Sunday, 06'th Aug 2023
On August 6, 2023, Gilead Sciences Inc ( GILD , Financial) experienced a day's change of 4.17%, with the stock price at $78.68. The company's Earnings Per Share (EPS) stood at 4.35.
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
02:17pm, Friday, 04'th Aug 2023
Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.
Is Gilead Sciences (GILD) Fairly Valued? An In-Depth Analysis
11:35am, Friday, 04'th Aug 2023
With a daily gain of 4.63% and an Earnings Per Share (EPS) of 4.43, Gilead Sciences Inc ( GILD , Financial) has been attracting attention in the investment community. This article aims to answer the p
Gilead Sciences (GILD) Q2 Earnings Lag Estimates
07:32pm, Thursday, 03'rd Aug 2023
Gilead Sciences (GILD) came out with quarterly earnings of $1.34 per share, missing the Zacks Consensus Estimate of $1.60 per share. This compares to earnings of $1.58 per share a year ago.
